The prognosis for patients with relapsed acute myeloid leukaemia (AML) is poor, and effective treatments for this patient group remain a substantially unmet clinical need. Elacytarabine is a promising new cytotoxic nucleoside agent made by an esterification reaction between cytarabine and elaidic acid, currently in development for use in the treatment of relapsed/refractory AML. Unlike cytarabine, cellular uptake of elacytarabine is independent of human equilibrative nucleoside transporter-1 (hENT-1) and results in prolonged intracellular retention of the active nucleoside. In addition, elacytarabine inhibits DNA synthesis for twice the duration seen with cytarabine and exhibits a different intracellular distribution. A Phase I trial in patients with AML identified a recommended dose of 2,000 mg/m²/day for five days and showed limited non-haematological side effects, liver toxicity being dose-limiting. Elacytarabine can be safely combined with idarubicin. A recent Phase II trial demonstrated an improved complete remission rate and overall survival with elacytarabine as a single agent in patients with advanced AML, as compared with a historical control group treated with second salvage therapy. Following these encouraging results, the results of an ongoing Phase III clinical trial comparing elacytarabine with the investigator's choice of standard of care are awaited with interest.
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In Europe, the incidence of AML in adults is 5-8 cases/100,000/year, while the mortality rate is 4-6 cases/100,000/year. 2 Treatment of AML consists of two phases: induction therapy, which aims to produce complete remission (CR), and post-remission (consolidation) therapy, which aims to prolong the CR. For the past 30 years, the standard induction therapy for AML has consisted of cytarabine in conjunction with an anthracycline, such as daunorubicin or idarubicin. 1 In general, following induction therapy, the CR rate is 50-75 % in adult patients. 1, 3, 4 The major determinants of prognosis for patients with AML are age, cytogenetics and FLT3/NPM1 gene mutation profile. 5 After CR, however, the majority of patients relapse, giving rise to a more resistant leukaemia. 6 The prognosis for relapsed or refractory AML patients is poor and there is no standard treatment. 7 For patients who achieve CR, AML may be curable by stem cell transplantation. The introduction of new drugs and therapeutic regimens that have been shown to achieve CR in a greater number of patients could potentially result in more transplants being performed, and consequently increased cure rates in relapsed or refractory AML patients. New therapies for the treatment of relapsed/refractory AML represent an unmet clinical need. This article will discuss the use of elacytarabine, a promising new agent in the treatment of relapsed/refractory AML.
Monophosphorylation of cytarabine by deoxycytidine kinase (dCK) is the rate-limiting step in intracellular conversion to ara-CTP. 11 The efficacy of cytarabine is heavily dependent on dose and schedule because of its short biological half-life. This is due to a rapid deamination into uracil arabinoside (ara-U) by the enzyme cytidine deaminase in the blood, liver, kidneys and intestine. 12 The chemotherapeutic efficacy of cytarabine varies dramatically between individuals, 13 with relapsed leukaemia representing a considerable therapeutic challenge. At least two distinct mechanisms of cytarabine resistance have been identified in leukaemic cells. 14 Resistance can be due to altered nucleoside transport (leading to a reduction in intracellular concentrations of the drug). 15, 16 Resistance can also result from reduced intracellular activation due to high deaminase activity (which inactivates cytarabine), low dCK activity (which decreases the production of active metabolites) 17 or high cytosolic 5'-nucleotidase II (which dephosphorylates cytarabine monophosphate to cytarabine).
18

Role of Nucleoside Transporters in Resistance to Cytarabine
Cytarabine is a hydrophilic molecule, and therefore its entry into tumour cells requires the expression of nucleoside-specific membrane transport carriers. The human equilibrative nucleoside transporter-1 (hENT1) is responsible for 80-90% of the total transmembrane transport of pyrimidine nucleosides 19 and 80 % of cytarabine influx into human leukaemic blast cells. 20 Transport of cytarabine into the cancer cell is important, as intracellular concentrations of ara-CTP correlate with clinical outcomes. 21 Further supporting this, it has been noted that some cancers have low levels of hENT1 and respond poorly to nucleoside analogues. 16 Several studies have further highlighted the association between hENT1, intracellular transport and cytarabine resistance. [22] [23] [24] It has been demonstrated in vitro that hENT1-deficient cells are highly resistant to cytarabine, while transfection with the hENT1 gene sensitised the cells to the drug. 24 Hubeek et al. found a significant correlation between hENT1 messenger RNA (mRNA) expression and in vitro response to cytarabine in 50 samples from paediatric AML patients (product-moment correlation [rp] -0.46, p=0.001), with threefold lower hENT1 mRNA levels found in resistant patients (p=0.003). 23 Additionally, in a study of 77 AML patients, deficient expression of hENT1 mRNA was associated with an increased risk of relapse and a significant reduction in long-term survival. 22 The importance of hENT1 was further illustrated in a study of 123 cytarabine-treated patients, where patient hENT1 deficiency was related to shorter disease-free survival. 25 The abundance of hENT1 is variable in AML patients; however, the number of nucleoside transport sites (NTSs) on blast cells has been noted to closely correlate with intracellular accumulation of ara-CTP 26 and sensitivity to cytarabine. 27 Gati et al. observed that within leukaemic myeloblasts from nine patients there was a sixfold variation in the number of hENT1 sites (as determined by flow cytometry and the use of a fluorescent hENT1-binding molecule). 27 In their study, sensitivity of leukaemic myeloblasts to cytarabine was shown to correlate with the abundance of functional nucleoside transporters. Wiley et al. also noted that the transport capacity of cytarabine into blast cells was directly related to the number of NTSs on the cell. 28 Low cytarabine transport rates or few NTSs on blasts were observed in a subset of patients with acute leukaemia who failed to achieve remission with drug combinations containing cytarabine. In addition to having a more favourable cellular uptake mechanism, elacytarabine also has a different intracellular distribution and inhibits DNA synthesis for twice the time of cytarabine. In C26G cells, DNA synthesis was inhibited for more than four hours after exposure to elacytarabine, while DNA synthesis had fully recovered after only two hours following exposure to cytarabine. 32 This longer period of inhibition may be due to slower intracellular release and prolonged intracellular retention of cytarabine and its active metabolites from elacytarabine. Within the cell, elacytarabine is predominantly located in the membrane proteins and cytosolic portions, unlike cytarabine, which is exclusively in the cytosol fraction. 29 To gain its cytotoxic activity, elacytarabine first undergoes hydrolysis to form cytarabine and is further converted to ara-CTP as previously described. Because of this conversion step, elacytarabine is not immediately available as a substrate for inactivation into ara-U by cytidine deaminase, 32 
Clinical Studies
Elacytarabine has the potential to overcome important mechanisms of resistance to cytarabine. As such, it addresses a major unmet A Phase I/II protocol (CP4055-106 study, ClinicalTrials.gov identifier NCT00405743) was designed to determine the safety and efficacy of elacytarabine in patients with AML receiving elacytarabine either as monotherapy or in combination with idarubicin (see Figure 4) . Trial arms A and B (dose escalation) enrolled a total of 77 patients with haematological malignancies; the majority presented with refractory/relapsed AML and most had received two or more previous chemotherapeutic regimens. 33, 34 Patients were treated on days 1-5 every three weeks; in arm A, 37 patients were treated at doses of 300-2,500 mg/m 2 /day administered as a two-or four-hour infusion; in arm B, 40 patients were treated at doses of 200-2,500 mg/m 2 /day given as a 24-hour continuous intravenous infusion (CIV).
Antileukaemic activity was observed at doses of 875 mg/m 2 /day and higher. Dose-limiting toxicities (DLTs) occurred at 2,500 mg/m 2 /day; these were increased bilirubin, aspartate aminotransferase elevation and increased alkaline phosphatase, all of which were reversible. Efficacy results for the three treatment arms of the Phase I trial are summarised in Table 1 .
ara-C = cytarabine; ara-U = uracil arabinoside. Source: adapted by permission from Macmillan Publishers Ltd: [Leukemia] (Giles FJ, Vey N, Rizzieri D, et al., Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies), 34 copyright (2012).
Following on from these Phase I results, the CP4055-106 Phase II trial was an open multicentre study of elacytarabine as a second salvage therapy in AML. 37 The primary endpoint of the trial was the rate of CR or CR with incomplete platelet recovery (CRp) (CR + CRp) and six-month survival. Secondary endpoints were median duration of CR + CRp and safety. Elacytarabine was administered at 2,000 mg/m 2 /day CIV for five days in a three-week course and patients were given one or two courses of induction therapy and one or two courses of consolidation therapy if indicated.
Sixty-one patients were included in the study. The efficacy of elacytarabine (CR + CRp and overall survival) was compared with a historical control group of AML patients receiving second salvage therapy (see Table 2 ). 38 In patients treated with elacytarabine, the 
Future Developments
The development of clinical assays that predict sensitivity and/or resistance to nucleoside anticancer drugs, and thus identify patient populations that will most probably benefit from optimal treatments, 16 would be a major step forwards in the treatment of AML. Recently, it was found that DNA methylation signatures can identify subtypes of AML and may effectively predict clinical outcomes. Its objectives are to determine the rate of CR or CR with insufficient haematological recovery (CRi), investigate the impact of hENT1 expression level on treatment activity, and characterise the safety profile of the treatment combination. 41 Although recruitment is still ongoing, interim results show that 48 % of the patients attained CR or CRi and that response to elacytarabine plus idarubicin was independent of hENT1 status. 42 A second objective of the trial is to investigate the responded to cytarabine-based induction therapy, whereas only one-third of patients with low hENT1 responded. These data indicate that hENT1 expression level could be used to target patients who are unlikely to benefit from conventional cytarabine therapy and should rather be treated with elacytarabine. A flow cytometry method suitable for hENT1 analysis in first-line AML patients is currently in development.
The aim is to facilitate the selection of patients who are most likely to benefit from elacytarabine rather than cytarabine, using a method that will be easy to integrate into standard leukaemia diagnostic practice.
Concluding Remarks
Despite increased understanding of the molecular pathophysiology 
